Alaunos Therapeutics, Inc. (NASDAQ:TCRT) Sees Large Decrease in Short Interest

Alaunos Therapeutics, Inc. (NASDAQ:TCRT) was the target of a significant drop in short interest in December. As of December 31st, there was short interest totalling 108,500 shares, a drop of 18.5% from the December 15th total of 133,100 shares. Based on an average daily volume of 24,000 shares, the short-interest ratio is presently 4.5 days. Approximately 7.9% of the company’s stock are short sold.

Alaunos Therapeutics Price Performance

Shares of Alaunos Therapeutics stock opened at $1.73 on Friday. The business has a 50-day moving average price of $2.10 and a 200 day moving average price of $2.84. Alaunos Therapeutics has a fifty-two week low of $1.63 and a fifty-two week high of $32.85.

About Alaunos Therapeutics

Alaunos Therapeutics, Inc, a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers.